Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.65 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.65 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.65 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.60 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.60 |
| ▸ | MME | P08473 | 1/20 | 0.59 |
| ▸ | CPA1 | P15085 | 1/20 | 0.59 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.59 |
| ▸ | CTSS | P25774 | 4/20 | 0.58 |
| ▸ | CTSK | P43235 | 3/20 | 0.58 |
| ▸ | CTSB | P07858 | 2/20 | 0.58 |
| ▸ | CTSL | P07711 | 1/20 | 0.58 |
| ▸ | MMP13 | P45452 | 1/20 | 0.57 |
| ▸ | PPARA | Q07869 | 5/20 | 0.57 |
| ▸ | PPARG | P37231 | 4/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | PPARD | Q03181 | 2/20 | 0.55 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.53 |
| ▸ | BCL2 | P10415 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3923929 | 1.00 | ACE (0.65) | ACEITGB3ITGA2BPTPN1SCN9A | |
| SCHEMBL3923937 | 1.00 | ACE (0.65) | ACEITGB3ITGA2BPTPN1SCN9A | |
| SCHEMBL2290444 | 1.00 | ACE (0.65) | ACEITGB3ITGA2BPTPN1SCN9A | |
| SCHEMBL2291767 | 0.94 | ITGB3 (0.71) | ACEITGB3ITGA2BPTPN1SCN9A | |
| SCHEMBL2291775 | 0.94 | ITGB3 (0.71) | ACEITGB3ITGA2BPTPN1SCN9A | |
| SCHEMBL2289496 | 0.94 | PPARA (0.66) | ACEITGB3ITGA2BPTPN1SCN9A | |
| SCHEMBL4739863 | 0.93 | ACE (0.60) | ACEITGB3ITGA2BPTPN1SCN9A | |
| SCHEMBL2296993 | 0.92 | PPARA (0.67) | ACEITGB3ITGA2BPTPN1SCN9A | |
| SCHEMBL2290585 | 0.90 | ITGB3 (0.62) | ACEITGB3ITGA2BPTPN1SCN9A | |
| SCHEMBL2290589 | 0.90 | ITGB3 (0.62) | ACEITGB3ITGA2BPTPN1SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522592-B2 | ERAP inhibitors | UNIVERSITE DE LILLE (FR) | 2026-01-13 | — | — | US | disclosed |
| US-20240101542-A1 | ERAP INHIBITORS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2024-03-28 | — | — | US | disclosed |
| CN-117043157-A | ERAP inhibitors | 里尔大学 | 2023-11-10 | — | — | CN | disclosed |
| WO-2009009035-A1 | SOMATOSTATIN ANALOG AND USES THEREOF | IPSEN PHARMA S.A.S. (FR) | 2009-01-15 | — | — | WO | disclosed |
| EP-1233013-B1 | NOVEL PHENYLALANINE DERIVATIVES | AJINOMOTO KK (JP) | 2007-02-28 | — | — | EP | disclosed |
| US-7160874-B2 | Phenylalanine derivatives | AJINOMOTO CO., INC. (JP) | 2007-01-09 | — | — | US | disclosed |
| US-20050070485-A1 | Antagonistic activity to alpha 4 integrin; treating asthma, rheumatoid arthritis; N-[1-N,N-dimethylaminocarbonylcyclopropane-1-ylcarbonyl]-4-({[5-chloro-2-(methylthio)pyrimidine-4-yl]carbonyl}-amino)-L-phenylalanine | AJINOMOTO CO., INC. (JP) | 2005-03-31 | — | — | US | disclosed |
| US-6855706-B2 | Phenylalanine derivatives | AJINOMOTO CO., INC. (JP) | 2005-02-15 | — | — | US | disclosed |
| US-20030149083-A1 | Phenylalanine derivatives | AJINOMOTO CO. INC (JP) | 2003-08-07 | — | — | US | disclosed |
| EP-1233013-A1 | NOVEL PHENYLALANINE DERIVATIVES | Ajinomoto Co., Inc. (JP) | 2002-08-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101542-A1 | ERAP INHIBITORS | ERAP2, ERAP1, ERMP1 | ACE 1149/4885ITGB3 4651/4885ITGA2B 4289/4885 |
| US-20030149083-A1 | Phenylalanine derivatives | ITGB4, ITGA4, ITGB3 | ACE 1910/4885ITGB3 3/4885ITGA2B 15/4885 |
| US-20050070485-A1 | Antagonistic activity to alpha 4 integrin; treating asthma, rheumatoid arthritis; N-[1-N,N-dimethylaminocarbonylcyclopropane-1-ylcarbonyl]-4-({[5-chloro-2-(methylthio)pyrimidine-4-yl]carbonyl}-amino)-L-phenylalanine | ITGB4, ITGA4, ITGAL | ACE 2440/4885ITGB3 8/4885ITGA2B 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.